vs
Orthofix Medical Inc.（OFIX）与Upstart Holdings, Inc.（UPST）财务数据对比。点击上方公司名可切换其他公司
Upstart Holdings, Inc.的季度营收约是Orthofix Medical Inc.的1.3倍（$296.1M vs $219.9M），Upstart Holdings, Inc.净利率更高（6.3% vs -1.0%，领先7.3%），Upstart Holdings, Inc.同比增速更快（35.2% vs 2.0%），Upstart Holdings, Inc.自由现金流更多（$108.4M vs $16.8M），过去两年Upstart Holdings, Inc.的营收复合增速更高（52.2% vs 8.0%）
Orthofix医疗是全球知名骨科医疗器械企业，专注于研发、生产及销售脊柱植入物、骨科创伤产品、骨生长刺激治疗设备及再生医疗产品，服务全球多地的骨科医师与医疗机构，致力于提升肌肉骨骼疾病患者的诊疗效果。
Upstart是一家AI信贷平台服务商，与银行及信用合作社合作，将教育背景、就业情况等非传统指标纳入信用评估模型，更精准地预测借款人的信用状况，为用户提供消费贷款服务，助力金融机构提升信贷效率、扩大服务覆盖范围。
OFIX vs UPST — 直观对比
营收规模更大
UPST
是对方的1.3倍
$219.9M
营收增速更快
UPST
高出33.3%
2.0%
净利率更高
UPST
高出7.3%
-1.0%
自由现金流更多
UPST
多$91.6M
$16.8M
两年增速更快
UPST
近两年复合增速
8.0%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $219.9M | $296.1M |
| 净利润 | $-2.2M | $18.6M |
| 毛利率 | 71.1% | — |
| 营业利润率 | 0.2% | 6.4% |
| 净利率 | -1.0% | 6.3% |
| 营收同比 | 2.0% | 35.2% |
| 净利润同比 | 92.4% | 776.4% |
| 每股收益（稀释后） | $-0.05 | $0.20 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收OFIXUPST
| Q4 25 | $219.9M | $296.1M | ||
| Q3 25 | $205.6M | $277.1M | ||
| Q2 25 | $203.1M | $257.3M | ||
| Q1 25 | $193.6M | $213.4M | ||
| Q4 24 | $215.7M | $219.0M | ||
| Q3 24 | $196.6M | $162.1M | ||
| Q2 24 | $198.6M | $127.6M | ||
| Q1 24 | $188.6M | $127.8M |
净利润OFIXUPST
| Q4 25 | $-2.2M | $18.6M | ||
| Q3 25 | $-22.8M | $31.8M | ||
| Q2 25 | $-14.1M | $5.6M | ||
| Q1 25 | $-53.1M | $-2.4M | ||
| Q4 24 | $-29.1M | $-2.8M | ||
| Q3 24 | $-27.4M | $-6.8M | ||
| Q2 24 | $-33.4M | $-54.5M | ||
| Q1 24 | $-36.0M | $-64.6M |
毛利率OFIXUPST
| Q4 25 | 71.1% | — | ||
| Q3 25 | 72.2% | — | ||
| Q2 25 | 68.7% | — | ||
| Q1 25 | 62.8% | — | ||
| Q4 24 | 69.0% | — | ||
| Q3 24 | 68.7% | — | ||
| Q2 24 | 67.8% | — | ||
| Q1 24 | 67.5% | — |
营业利润率OFIXUPST
| Q4 25 | 0.2% | 6.4% | ||
| Q3 25 | -8.3% | 8.5% | ||
| Q2 25 | -7.9% | 1.8% | ||
| Q1 25 | -25.2% | -2.1% | ||
| Q4 24 | -5.3% | -2.2% | ||
| Q3 24 | -9.6% | -27.8% | ||
| Q2 24 | -12.5% | -43.5% | ||
| Q1 24 | -15.6% | -52.8% |
净利率OFIXUPST
| Q4 25 | -1.0% | 6.3% | ||
| Q3 25 | -11.1% | 11.5% | ||
| Q2 25 | -6.9% | 2.2% | ||
| Q1 25 | -27.4% | -1.1% | ||
| Q4 24 | -13.5% | -1.3% | ||
| Q3 24 | -13.9% | -4.2% | ||
| Q2 24 | -16.8% | -42.7% | ||
| Q1 24 | -19.1% | -50.5% |
每股收益（稀释后）OFIXUPST
| Q4 25 | $-0.05 | $0.20 | ||
| Q3 25 | $-0.57 | $0.23 | ||
| Q2 25 | $-0.36 | $0.05 | ||
| Q1 25 | $-1.35 | $-0.03 | ||
| Q4 24 | $-0.76 | $-0.01 | ||
| Q3 24 | $-0.71 | $-0.07 | ||
| Q2 24 | $-0.88 | $-0.62 | ||
| Q1 24 | $-0.95 | $-0.74 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $82.0M | $652.4M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $450.0M | $798.8M |
| 总资产 | $850.6M | $3.0B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资OFIXUPST
| Q4 25 | $82.0M | $652.4M | ||
| Q3 25 | $62.9M | $489.8M | ||
| Q2 25 | $65.6M | $395.9M | ||
| Q1 25 | $58.0M | $599.8M | ||
| Q4 24 | $83.2M | $788.4M | ||
| Q3 24 | $30.1M | — | ||
| Q2 24 | $26.4M | — | ||
| Q1 24 | $27.0M | — |
总债务OFIXUPST
| Q4 25 | — | — | ||
| Q3 25 | $157.2M | — | ||
| Q2 25 | $157.0M | — | ||
| Q1 25 | $156.9M | — | ||
| Q4 24 | $157.0M | — | ||
| Q3 24 | $118.5M | — | ||
| Q2 24 | $118.0M | — | ||
| Q1 24 | $118.2M | — |
股东权益OFIXUPST
| Q4 25 | $450.0M | $798.8M | ||
| Q3 25 | $442.5M | $743.7M | ||
| Q2 25 | $458.3M | $722.0M | ||
| Q1 25 | $458.3M | $676.6M | ||
| Q4 24 | $503.1M | $633.2M | ||
| Q3 24 | $525.9M | $595.5M | ||
| Q2 24 | $546.0M | $594.7M | ||
| Q1 24 | $570.3M | $612.8M |
总资产OFIXUPST
| Q4 25 | $850.6M | $3.0B | ||
| Q3 25 | $832.6M | $2.9B | ||
| Q2 25 | $837.2M | $2.5B | ||
| Q1 25 | $823.1M | $2.3B | ||
| Q4 24 | $893.3M | $2.4B | ||
| Q3 24 | $867.9M | $1.8B | ||
| Q2 24 | $882.0M | $1.8B | ||
| Q1 24 | $906.0M | $1.9B |
负债/权益比OFIXUPST
| Q4 25 | — | — | ||
| Q3 25 | 0.36× | — | ||
| Q2 25 | 0.34× | — | ||
| Q1 25 | 0.34× | — | ||
| Q4 24 | 0.31× | — | ||
| Q3 24 | 0.23× | — | ||
| Q2 24 | 0.22× | — | ||
| Q1 24 | 0.21× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $27.7M | $108.6M |
| 自由现金流经营现金流 - 资本支出 | $16.8M | $108.4M |
| 自由现金流率自由现金流/营收 | 7.6% | 36.6% |
| 资本支出强度资本支出/营收 | 4.9% | 0.1% |
| 现金转化率经营现金流/净利润 | — | 5.82× |
| 过去12个月自由现金流最近4个季度 | $-1.3M | — |
8季度趋势，按日历期对齐
经营现金流OFIXUPST
| Q4 25 | $27.7M | $108.6M | ||
| Q3 25 | $12.4M | $-122.6M | ||
| Q2 25 | $11.6M | $-120.2M | ||
| Q1 25 | $-18.4M | $-13.5M | ||
| Q4 24 | $23.7M | $-110.9M | ||
| Q3 24 | $11.7M | $179.3M | ||
| Q2 24 | $9.0M | $65.3M | ||
| Q1 24 | $-18.6M | $52.6M |
自由现金流OFIXUPST
| Q4 25 | $16.8M | $108.4M | ||
| Q3 25 | $2.5M | $-122.7M | ||
| Q2 25 | $4.5M | $-120.3M | ||
| Q1 25 | $-25.1M | — | ||
| Q4 24 | $15.2M | — | ||
| Q3 24 | $6.3M | $179.2M | ||
| Q2 24 | $-360.0K | $65.3M | ||
| Q1 24 | $-29.1M | $51.9M |
自由现金流率OFIXUPST
| Q4 25 | 7.6% | 36.6% | ||
| Q3 25 | 1.2% | -44.3% | ||
| Q2 25 | 2.2% | -46.7% | ||
| Q1 25 | -13.0% | — | ||
| Q4 24 | 7.0% | — | ||
| Q3 24 | 3.2% | 110.5% | ||
| Q2 24 | -0.2% | 51.1% | ||
| Q1 24 | -15.4% | 40.6% |
资本支出强度OFIXUPST
| Q4 25 | 4.9% | 0.1% | ||
| Q3 25 | 4.8% | 0.0% | ||
| Q2 25 | 3.5% | 0.0% | ||
| Q1 25 | 3.5% | 0.0% | ||
| Q4 24 | 4.0% | 0.0% | ||
| Q3 24 | 2.7% | 0.1% | ||
| Q2 24 | 4.7% | 0.0% | ||
| Q1 24 | 5.6% | 0.5% |
现金转化率OFIXUPST
| Q4 25 | — | 5.82× | ||
| Q3 25 | — | -3.86× | ||
| Q2 25 | — | -21.43× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
OFIX
| Spinal Implants Biologics And Enabling Technologies | $113.6M | 52% |
| Bone Growth Therapies | $68.3M | 31% |
| Other | $22.7M | 10% |
| IT | $5.9M | 3% |
| GB | $3.5M | 2% |
| FR | $3.5M | 2% |
| DE | $2.3M | 1% |
UPST
| Personal Lending Segment | $201.4M | 68% |
| Servicing Fees Net | $39.5M | 13% |
| Servicing Fees | $27.5M | 9% |
| Other | $15.7M | 5% |
| Borrower Fees | $8.4M | 3% |
| Collection Agency Fees | $3.5M | 1% |
